December 12, 2025 16:30 ET | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) --…
LUXEMBOURG and PARIS, Dec. 10, 2025 /PRNewswire/ -- FitLine is proud to announce a new partnership with Paris Basketball, the…
LEUVEN, BELGIUM – Euro NCAP’s independent assessment of the new CLA shows an outstanding safety performance with a five-star result…
December 10, 2025 04:00 ET | Source: Igyxos TOURS, France, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Igyxos Biotherapeutics, a biotechnology…
INNSBRUCK, Austria, Dec. 9, 2025 /PRNewswire/ -- As cyberattacks continue to challenge even the most resilient organisations, the need for…
Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction in countable motor seizure frequency (CMSF)…
December 06, 2025 17:30 ET | Source: Fulcrum Therapeutics, Inc. ― Clear dose-response observed, with a robust and clinically meaningful…
December 05, 2025 21:00 ET | Source: Cerevance, Inc. Phase 2 results selected as one of only 10 featured presentations…
Topline results from Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected in the second half of 2026Topline results from…
DALLAS, Dec. 2, 2025 /PRNewswire/ -- On December 1, Cango Inc. (NYSE: CANG) ("Cango" or the "Company") announced its unaudited…